Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE DLBCL-3: Epcoritamab With or Without Lenalidomide in Anthracycline-ineligible Newly Diagnosed DLBCL
jRCT2021230015Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Epcoritamab monotherapy with Epcoritamab + lenalidomide (2 arms). Primary endpoint: Complete Response (CR) rate. Started Nov 2023; status: active, not recruiting.
02
Drugs
epcoritamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2021230015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230015.